display
The vaccine from Johnson & Johnson is apparently threatened with a fate similar to that of AstraZeneca: As the "Spiegel" reports, citing anonymous sources, the Standing Vaccination Commission (Stiko) only wants to recommend it for people over 60 on Monday. Younger people should be allowed to continue receiving the vaccine after being informed by a doctor. The press office of the Robert Koch Institute confirmed that they expected a statement from Stiko on Monday. According to "Spiegel", however, a spokesman did not want to comment on what this would look like.
Similar to AstraZeneca, with the Johnson & Johnson vaccine, blood clots have been observed in isolated cases after vaccination. The USA had therefore temporarily suspended vaccinations with the active ingredient. The vaccine has been approved in the EU since March, but has rarely been administered there. Because of the thrombosis cases in the USA, the manufacturer temporarily stopped the delivery planned for mid-April.
After an examination of the blood clot cases that occurred in the USA, the EU Medicines Agency Ema recently stated that it would stick to its recommendation for the vaccine.
However, blood clots should be included in the list of “very rare” side effects.
The Johnson & Johnson vector vaccine has the advantage that it is easy to store compared to other active ingredients.
In addition, only one dose is necessary for immunization.
display
Buy antigen self-tests online now
More security and better risk assessment through quick self-tests.
Order 1 nasal swab test from Amazon Order 5 nasal swab tests from Amazon Order 2 spit tests from Tchibo
All developments in the live ticker